$IPHA

Innate Pharma S.A. (IPH.PA) stock is up 8.94% today as traders anticipate its earnings release on March 26, 2026. Key focuses for the earnings call will be updates on Phase III Monalizumab and Phase II Lacutamab clinical programs, cash runway, and potential partnership milestones. Meyka AI gives IPH.PA a "HOLD" rating with an estimated 18.80% upside, but highlights risks such as high debt-to-equity and potential dilution.